the aid library

LIST OPTIONS

Filter

8973

Sort by:

Direction:

Download (143)

View PDF (135)

Global technical consultation report on proposed terminology for pathogens that transmit through the air

World Health Organization WHO (2024) C_WHO

Terminology used to describe the transmission of pathogens through the air varies across scientific disciplines, organizations and the general public. While this has been the case for decades, during the coronavirus disease (COVID-19) pandemic, the terms ‘airborne’, ‘airborne transmission’ a... more

Download (116)

View PDF (122)

Reclaim the Gains - The Case for Investing in the Global Financing Facility 2021–2025

Global Financing Facility (GFF) Global Financing Facility (GFF) (2021) CC

The GFF needs an additional US$2.5 billion from 2021 to 2025 to enable countries to protect health gains and accelerate progress toward the 2030 Goals. Of this amount, the GFF urgently needs to secure new pledges of US$1.2 billion by the end of 2021 to help its current 36 partner countries protect ... more

Download (117)

View PDF (133)

Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995-2015

Global Burden of Disease Health Financing Collaborator Network Lancet (2018) CC

Background: Comparable estimates of health spending are crucial for the assessment of health systems and to optimally deploy health resources. The methods used to track health spending continue to evolve, but little is known about the distribution of spending across diseases. We developed improved e... more

Download (149)

View PDF (150)

Building better immunity: A life course approach to healthy longevity

Pan American Health Organization PAHO (2023) C_WHO

As the Americas undergo profound demographic change and there are more persons aged 65 years or older than children younger than 5 years, it is crucial to recognize that national immunization programs must be redesigned to ensure comprehensive protection for individuals across the lifespan. By adopt... more

Download (175)

View PDF (230)

WHO global air quality guidelines: particulate matter (‎PM2.5 and PM10)‎, ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide

World Health Organization WHO (2021) C_WHO

The global burden of disease associated with air pollution exposure exacts a massive toll on human health worldwide: exposure to air pollution is estimated to cause millions of deaths and lost years of healthy life annually. The burden of disease attributable to air pollution is now estimated to be ... more

Download (141)

View PDF (163)

WHO global report on trends in prevalence of tobacco use 2000-2025

World Health Organization WHO (2021) C_WHO

Progress in reducing tobacco use is a key indicator for measuring countries’ efforts to implement the WHO Framework Convention on Tobacco Control – target 3.a under the Sustainable Development Goals agenda. Countries have adopted this indicator to report progress also towards the tobacco reducti... more

Download (274)

View PDF (144)

WHO Emergency Response Framework - Internal WHO procedures - Second Edition

World Health Organization WHO (2024) C_WHO

The ERF provides WHO staff with essential guidance on how the Organization manages the assessment, grading and response to public health events and emergencies with health consequences, in support of Member States and affected communities. The ERF adopts an all-hazards approach and it is therefore a... more

Download (101)

View PDF (222)

Financing Maternal and Child Health—What Are the Limitations in Estimating Donor Flows and Resource Needs?

Schäferhoff, M.; Schrade, C.; Yamey G. PLOS Med (2010) CC

Marco Schäferhoff and colleagues critique funding estimates for the maternal and child health Millennium Development Goals, and make recommendations for improving the tracking of financing flows and estimating the costs of scaling up interventions for mothers and children.

Download (262)

View PDF (235)

A checklist for respiratory pathogen pandemic preparedness planning

World Health Organization WHO (2023) C_WHO

This checklist is an operational tool to help national authorities develop or revise national respiratory pathogen (inclusive of influenza and coronaviruses) pandemic preparedness plans.

Download (291)

View PDF (389)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (163)

View PDF (174)

Pre-referral treatment with rectal artesunate of children with suspected severe malaria: a field guide

World Health Organization WHO (2023) C_WHO

Prompt, effective antimalarial treatment, and supportive care can substantially reduce the rate of mortality from severe malaria. However, many children in malaria-endemic countries do not have access to health facilities or a qualified health care provider and do not receive the necessary care in a... more

Download (217)

View PDF (197)

A Roadmap to combat postpartum haemorrhage between 2023 and 2030

World Health Organization WHO (2023) C_WHO

WHO today released its first roadmap to tackle postpartum haemorrhage (PPH) – defined as excessive bleeding after childbirth - which affects millions of women annually and is the world’s leading cause of maternal deaths. Despite being preventable and treatable, PPH results in around 70 000 de... more

Download (145)

View PDF (140)

WHO Guide to conducting programme reviews for HIV, viral hepatitis and sexually transmitted infections

World Health Organization WHO (2023) C_WHO

Sound periodic programme reviews provide opportunities for countries to objectively assess progress and take corrective action to sustain or get back on track towards achieving their medium and long-term programme goals. It reflects people’s diverse needs, enables efficient use of health system re... more

Download (211)

View PDF (336)

WASH FIT: Manual for Trainer

UN Children's Fund UNICEF; World Health Organization WHO (2023) C_WHO

The Water and Sanitation for Health Facility Improvement Tool (WASH FIT) presents a framework and acts as a guide to support multisectoral action to improve water, sanitation and hygiene (WASH) in health care. Central to the WASH FIT methodology is training and incremental improvements. Implementat... more

Download (175)

View PDF (189)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 10 August 2023

World Health Organization WHO (2023) C_WHO

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Download (296)

View PDF (265)

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended

World Health Organization WHO (2023) CC

Ebola disease and Marburg disease outbreaks continue to occur in Africa, with increased frequency. In addition to resulting in high mortality and morbidity, the outbreaks generate fear and mistrust about the response activities within the communities affected. Infection prevention and control (IP... more

Download (159)

View PDF (176)

Clinical management of COVID-19: Living guideline, 18 August 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO COVID-19 Clinical management: living guidance contains the most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is important.

Download (232)

View PDF (209)

Global oral health status report: towards universal health coverage for oral health by 2030: regional summary of the Western Pacific Region

World Health Organisation (WHO) (2023) C_WHO

This regional summary draws on the WHO Global oral health status report (2), published in 2022, which provides a comprehensive overview of the global oral disease burden, the global health importance of oral health and the impact of oral diseases over the life course. The summary focuses on the ... more

Download (323)

View PDF (489)

Trends and mortality effects of vitamin A deficiency in children in 138 low-income and middle-income countries between 1991 and 2013: a pooled analysis of population-based surveys

Stevens, Gretchen; Bennett, James et al. (2015) CC

Vitamin A deficiency is a risk factor for blindness and for mortality from measles and diarrhoea in children aged 6–59 months. We aimed to estimate trends in the prevalence of vitamin A defi ciency between 1991 and 2013 and its mortality burden in low-income and middle-income countries.

Download (379)

View PDF (284)

The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines. F10 - F19 Mental and behavioural disorders due to psychoactive substance use

World Health Organization (WHO) (1992) C_WHO

This block contains a wide variety of disorders that differ in severity (from uncomplicated intoxication and harmful use to obvious psychotic disorders and dementia), but that are all attributable to the use of one or more psychoactive substances (which may or may not have been medically prescribed)

Infection prevention and control guideline for Ebola and Marburg disease, August 2023 recommended

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended